A number of laboratories, including those involved in this Program Project, have demonstrated that Adeno-associated virus holds significant promise for the correction of human disease. These experiments have shown that AAV can be used to transfer genes into primary cells both in vivo and ex vivo. However, if the development of AAV as a vector is to move forward several issues must be addressed about the basic biology of AAV. First, the AAV terminal repeats, which are absolutely required for DNA replication, integration and packaging, have not been completely characterized. The terminal repeats, which are absolutely required for DNA replication, integration and packaging, have not been completely characterized. The terminal repeats (TRs) consist of several elements that we and others have identified, including, the Rep binding element (RBE), the CTTTG motif within the B and C palindromes, the terminal resolution site (trs) and the secondary structure of the TR. Although a substantial amount of information has accumulated about the RBE, no one has yet determined the precise sequences within the trs or the CTTTG motif that are essential for DNA replication, nor has anyone investigated the spatial and orientation requirements of the elements within the TR for Rep functions. Additionally, no one has clearly demonstrated which multimeric Rep complex is functional for trs nicking or DNA helicase activity. Second, although it is clear that both AAV DNA replication and latency require cellular replication and/or repair enzymes, nothing is known about the enzymes that are involved. We recently developed an in vitro AAV DNA replication assay which faithfully recapitulates the mechanism of AAV DNA replication. We propose to use this assay to identify and characterize the cellular enzymes required for AAV DNA replication using standard biochemical fractionation and reconstitution techniques. Our goal is to reconstitute AAV DNA replication in vitro with purified enzymes. Finally, relatively little is known about the functional regions of the AAV capsid or the mechanism of encapsidation. For this reason we will isolate and characterize mutations within the AAV capsid proteins to identify functional regions within the capsid gene required for packaging. These mutations will be useful for designing rAAV vectors that are capable for targeting specific cell types. We will also take advantage of our recently developed in vitro packaging reaction to study the mechanism of AAV encapsidation.
Our specific aims are: 1: Characterization of the AAV origin sequences and their interaction with Rep protein. 2: Purification and identification of cellular DNA replication enzymes required for AAV DNA replication in vitro. 3: To study AAV DNA packaging and capsid structure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL051811-07
Application #
6318398
Study Section
Project Start
2000-04-01
Project End
2001-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
7
Fiscal Year
2000
Total Cost
$270,973
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Kates, Max; Date, Abhijit; Yoshida, Takahiro et al. (2017) Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer. Clin Cancer Res 23:6592-6601
Guggino, William B; Benson, Janet; Seagrave, JeanClare et al. (2017) A Preclinical Study in Rhesus Macaques for Cystic Fibrosis to Assess Gene Transfer and Transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter System. Hum Gene Ther Clin Dev 28:145-156
Schuster, Benjamin S; Allan, Daniel B; Kays, Joshua C et al. (2017) Photoactivatable fluorescent probes reveal heterogeneous nanoparticle permeation through biological gels at multiple scales. J Control Release 260:124-133
Schneider, Craig S; Xu, Qingguo; Boylan, Nicholas J et al. (2017) Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci Adv 3:e1601556
Duncan, Gregg A; Jung, James; Joseph, Andrea et al. (2016) Microstructural alterations of sputum in cystic fibrosis lung disease. JCI Insight 1:e88198
Yu, Tao; Chisholm, Jane; Choi, Woo Jin et al. (2016) Mucus-Penetrating Nanosuspensions for Enhanced Delivery of Poorly Soluble Drugs to Mucosal Surfaces. Adv Healthc Mater 5:2745-2750
Schuster, Benjamin S; Ensign, Laura M; Allan, Daniel B et al. (2015) Particle tracking in drug and gene delivery research: State-of-the-art applications and methods. Adv Drug Deliv Rev 91:70-91
Mastorakos, Panagiotis; da Silva, Adriana L; Chisholm, Jane et al. (2015) Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci U S A 112:8720-5
Schuster, Benjamin S; Kim, Anthony J; Kays, Joshua C et al. (2014) Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. Mol Ther 22:1484-1493
Cebotaru, Liudmila; Guggino, William B (2014) Complement yourself: Transcomplementation rescues partially folded mutant proteins. Biophys Rev 6:169-180

Showing the most recent 10 out of 123 publications